ReviewJournal of clinical medicine2026
Current and Emerging Strategies for Myopia Control in Children: A Comprehensive Evidence-Based Review.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Combined Small Treatment Zone Orthokeratology and Alternate-Day 0.01% Atropine for Axial Elongation Control in Rapidly Progressing Myopic Children.Translational vision science & technology · 2026Trial
- Myopia as a Global Public Health Challenge a Narrative Review.Life (Basel, Switzerland) · 2026Review
- The influence of age in the progression from pre-myopia to myopia onset: a 1 year retrospective analysis.Frontiers in medicine · 2026Article
- The "Three-Tier Regulatory Network" of Orthokeratology in Myopia Control: Evidence Weight of Underlying Mechanisms, Controversies, and New Perspectives for Clinical Translation--A Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Defining the critical axial length threshold for transition from physiological growth to pathological fundus structural remodeling in adolescent myopia.Frontiers in cell and developmental biology · 2026Article
- Comparison of myopia control efficacy between single vision and highly aspherical Lenslet spectacle lenses in children with low myopia: a 1-year retrospective study.Frontiers in medicine · 2026Article
- Effects of a recess-based ocular muscle regulation training program on visual function in adolescents: a school-based controlled study.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myopia has emerged as a global public health crisis, with prevalence exceeding 80% in East Asian urban populations and rising rapidly worldwide. High myopia substantially increases the lifetime risk of sight-threatening complications, including myopic macular degeneration, retinal detachment, and glaucoma. Multiple interventions have been investigated to slow myopia progression in children. Behavioral strategies, particularly increased outdoor exposure, demonstrate protective effects against myopia onset and may modestly slow progression, whereas several historically used approaches show no clinically meaningful benefit. Spectacle lens interventions include simultaneous defocus designs (e.g., DIMS, HALT, CARE) and contrast-modulating diffusion optics (DOT) lenses; collectively, these technologies have demonstrated consistent and clinically meaningful reductions in axial elongation across randomized clinical trials. Contact lens modalities, including dual-focus soft lenses and orthokeratology, have also demonstrated substantial efficacy in slowing progression in controlled studies. Low-dose atropine remains a cornerstone pharmacological therapy, particularly at concentrations between 0.01% and 0.05%, offering significant efficacy with minimal side effects. Repeated low-level red-light therapy has shown promising short-term reductions in axial elongation, although long-term safety and rebound effects remain uncertain. Combination therapy targeting complementary optical and pharmacological pathways shows additive benefits, particularly in children inadequately controlled with monotherapy. Contemporary clinical management emphasizes risk stratification based on axial length, age-specific growth targets, and structured longitudinal monitoring. The goal of modern myopia management is not merely to slow progression, but to prevent high myopia and reduce the lifetime burden of vision-threatening complications through a proactive, individualized approach increasingly regarded as the standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.